Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia in western countries, with an incidence of 5.82/100000 inhabitants in the USA (Li et al.,2015). The median age at diagnosis is 72 years, with a higher incidence in males (1.7:1) (Li et al.,2015; Hallek,2017; ...
lymphocytic lymphomaThe Kiel classification of non-Hodgkin lymphomas (NHL) has established chronic lymphocytic leukemia (B-CLL) and immunocytoma (LP-IC) as separate entities of low-grade malignant NHL by morphological and immunohistochemical criteria. The clinical and prognostic relevance of this ...
The article discusses the significance of ibrutinib in the overall survival over chlorambucil monotherapy in patients with chronic lymphocytic leukemia (CLL). Topics include the use of Ibrutinib for previously treated patients with CLL and as a therapy for patients with del (17p) CLL, the endpoints...
展开 关键词: Chronic lymphocytic leukaemia Small lymphocytic lymphoma (SLL Monoclonal B-cell lymphocytosis Cell of origin V H mutated V H unmutated Typical CLL CLL mixed type Prolymphocytic leukaemia Prolymphocyte DOI: 10.1007/978-1-4614-3764-2_7 年份: 2013 收藏...
Waage A, Espevik T. TNF receptors in chronic lymphocytic leukemia. Leuk Lymphoma 1994; 13: 41–46. ArticlePubMedCASGoogle Scholar Adami F, Guarini A, Pini M, et al. Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia. Eur J Cancer 1994; 30A...
Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic leukemia (CLL) that develops within hours of starting drug and is due to ... SEM Herman,RZ Mustafa,J Jones,... - 《Clinical Cancer Research An Official Journal of the American Association for Cancer Research》 被...
We also screened individuals for monoclonal B-cell lymphocytosis, or which is the precursor to CLL. We wanted to see if this score would also help predict individuals with this precursor condition if they progress to having chronic lymphocytic leukemia. This precursor condition is very common in ...
lymphoma (SLL) efficacy cohort, 247 patients received pirtobrutinib after prior treatment with a BTKi, with a median of 3 prior therapies. The ORR was 82.2% when including partial responses in patients with lymphocytosis (73.3% when excluding patients with lymphocytosis). After a median follow-...
Ysebaert L, Klein C, Quillet-Mary A. CLL cells from ibrutinib-induced lymphocytosis of relapsed/refractory chronic lymphocytic leukemia patients are responsive to obinutuzumab, but not rituximab, ex vivo. Blood. 2015;126:4157. Google Scholar Hallek M. Signaling the end of chronic lymphocytic le...
Approximately 80 % of chronic lymphocytic leukemia (CLL) carries somatically acquired genomic copy number aberrations (aCNAs). These include gains of entire chromosomes (trisomy 12) and recurrent genomic losses, including interstitial deletions of variou